Inclusion Criteria:

          1. Signed informed consent form

          2. Documentation of CD19 expression on malignant cells

               1. CLL: At time of most recent relapse

               2. NHL: Within 6 months of physician-investigator confirmation of eligibility as
                  long as there has been no intervening CD19 directed therapy since expression
                  confirmed. Results outside of this window may be used, if there is no accessible
                  tumor site and the subject did not receive intervening CD19 directed therapy
                  since CD19 expression was confirmed.

          3. Patients with relapsed disease after prior allogeneic SCT must meet the following
             criteria:

               1. Have no active GVHD and require no immunosuppression

               2. Are more than 6 months from transplant at the time of physician-investigator
                  confirmation of eligibility

          4. Adequate organ function defined as:

             a. Creatinine ≤ 1.6 mg/dl b. ALT/AST ≤ 3x upper limit of normal range c. Direct
             bilirubin ≤ 2.0 mg/dl, unless the subject has Gilbert's syndrome (≤3.0 mg/dl) d. Must
             have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse
             oxygen > 92% on room air e. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by
             ECHO/MUGA

          5. Evidence of active disease. This could include circulating disease in the blood,
             disease in the bone marrow by standard morphology, or in NHL patients, measurable
             disease per Lugano criteria.

          6. Male or female age ≥ 18 years.

          7. ECOG Performance Status that is either 0 or 1.

          8. Subjects of reproductive potential must agree to use acceptable birth control methods,
             as described in protocol

          9. Disease-specific criteria:

             a. Chronic Lymphocytic Leukemia (CLL): i. Patients with relapsed/refractory disease
             after at least 2 prior lines of appropriate therapy; and ii. Patients must have
             previously received, or be intolerant to an approved BTK inhibitor and venetoclax,
             unless a BTK inhibitor or venetoclax is contraindicated.

             b. Non-Hodgkin Lymphoma (NHL): i. Patients with any of the following diagnoses:
             Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS), germinal center or
             activated B-cell types; Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large
             B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma
             with MYC and BCL2 and/or BCL6 rearrangements (i.e. "Double or Triple Hit"); High-grade
             B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or
             any aggressive B-cell lymphoma arising from indolent lymphoma.

        1. Patients must have either relapsed after, or be ineligible for, prior CAR T cell
        therapy, and meet one of the following criteria:

          1. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy and
             are ineligible for autologous stem cell transplant or commercial CAR T cell therapy.

          2. Relapsed/refractory disease after autologous SCT.

          3. Relapsed/refractory disease after allogeneic SCT. ii. Follicular lymphoma 1. Patients
             who have received at least 2 prior lines of appropriate therapy (not including single
             agent monoclonal antibody therapy) and progressed within 2 years after second or
             higher line of therapy.

        iii. Mantle cell lymphoma

          1. Patients must have either failed or be ineligible for standard of care Tecartus™
             (brexucabtagene autoleucel) or other investigational CAR T cell product; and

          2. Patients must also meet one of the following criteria:

               1. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy,
                  including a BTK inhibitor. Single-agent monoclonal antibody therapy does not
                  count towards prior lines of therapy.

               2. Relapsed/refractory disease after prior autologous SCT.

               3. Relapsed/refractory disease after prior allogeneic SCT. iv. Large cell
                  transformation of CLL (Richter's Transformation)

        1. Patients must be primary refractory or received at least 1 prior line of treatment.

        Exclusion Criteria:

          1. Active hepatitis B, active hepatitis C, or other active, uncontrolled infection.

          2. Class III/IV cardiovascular disability according to the New York Heart Association
             Classification

          3. Clinically apparent arrhythmia or arrhythmias that are not stable on medical
             management within two weeks of physician-investigator confirmation of eligibility.

          4. Active acute or chronic GVHD requiring systemic therapy.

          5. Dependence on systemic steroids or immunosuppressant medications. For additional
             details regarding use of steroid and immunosuppressant medications

          6. Receipt of immune checkpoint inhibitors within 4 months prior to
             physician-investigator confirmation of eligibility.

          7. Receipt of prior huCART19 therapy.

          8. Active CNS disease. Note: Patients with a history of CNS involvement that was
             successfully treated are eligible. A CNS evaluation is only required for eligibility
             if a subject is experiencing signs/symptoms of CNS involvement.

          9. Pregnant or nursing (lactating) women.

         10. Patients with a known history or prior diagnosis of optic neuritis or other
             immunologic or inflammatory disease affecting the central nervous system, and
             unrelated to their cancer or previous cancer treatment.

         11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to
             ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will
             be excluded.